Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,176.00+6.17%ETH$2,634.91+7.58%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
EM

OTC · EMMA

Emmaus Life Sciences, Inc.

Healthcare · Biotechnology

$0.07

Up+$0.01 (+17.60%)

Updated Sep 18, 2026, 9:11 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
702.52K
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.01 – $0.09
Volume
345.5K
Avg. volume
69.57K

Price performance

EMMA price history

1M range · 0 trading sessions · Daily adjusted prices

EMMA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest EMMA news

The latest Smart Investors Daily articles mentioning EMMA.

Stock researchCompany · Overview

EMMA research

Overview

Company profile and research snapshot.

Company profile

EMMAUS LIFE SCIENCES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

TORRANCE, Calif., August 31, 2026--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC).

Benzinga · Nov 14, 2025

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences reported a 38% decline in net revenues for Q3 2025, attributed to generic L-Glutamine competition and lower sales in the Middle East North Africa region. The company experienced a net loss of $2.1 million and reduced operating expenses by 43%.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By